As an innovative form of combining traditional aromatherapy with modern nasal medicine delivery technology， "olfactory administration of Chinese medicine" carries the theoretical essence of traditional Chinese medicine （TCM）， which is "moving and channeling Qi and fragrance， dredging and awakening the mind". Based on the systematic records of olfactory therapies in ancient books in emergency care， disorders of consciousness， lung system， and gynecological diseases， this paper examines the historical evolution of its clinical application， and elucidates the profound historical basis and theoretical feasibility of "olfactory administration of Chinese medicine" as a new form. Combined with the innovation and precise application of modern Chinese medicine olfactory agents in multi-system diseases such as nervous， respiratory， and cardiovascular diseases， this paper further analyzes the multi-dimensional mechanism of olfactory receptor pathway， olfactory brain pathway， nasal mucosal blood vessels， and lymphatic channels， and demonstrates its advantages of rapid onset， targeted brain entry， and systemic regulation. Under the background of continuous growth in the demand for external TCM treatment， continuous breakthroughs in the technology of nasal dosage forms， and increasingly accurate drug delivery paths， Chinese medicine olfactory agents have shown significant practical applicability and development potential. This study aims to provide theoretical support and practical direction for the system construction of this form.

Alzheimer's disease(AD)is common neurodegenerative diseases that is the main causes of cognitive dysfunction and behavioral abnormalities.Constructing animal models with similar characteristics to human patients is crucial for advancing investigations of AD,and to develop new therapeutic drugs.Combined with the latest research progress,this review classifies animal models of AD according to aging models,genetically modified models,and chemically induced models.This review systematically summarizes the commonly used animal models of AD,and elucidates the modeling mechanisms and pathological changes,and compares their advantages and limitation,with a view to provide method ological references for researchers in selecting appropriate animal model for AD investigation.

Alzheimer's disease(AD)is common neurodegenerative diseases that is the main causes of cognitive dysfunction and behavioral abnormalities.Constructing animal models with similar characteristics to human patients is crucial for advancing investigations of AD,and to develop new therapeutic drugs.Combined with the latest research progress,this review classifies animal models of AD according to aging models,genetically modified models,and chemically induced models.This review systematically summarizes the commonly used animal models of AD,and elucidates the modeling mechanisms and pathological changes,and compares their advantages and limitation,with a view to provide method ological references for researchers in selecting appropriate animal model for AD investigation.

Chronic glomerulonephritis （CGN） is a common clinical chronic glomerular disease caused by autoimmune reaction， the pathogenesis of which is complex and has not been fully elucidated. There is no specific treatment method in modern medicine. The establishment of an animal model of CGN in accordance with its characteristics in western medicine and traditional Chinese medicine will help to reveal the pathogenesis of CGN， rate drugs， and improve the treatment plan. Based on the clinical diagnostic criteria of CGN， the paper establishes the syndrome differentiation criteria of CGN for Chinese and western medicine. Through summarizing the literature on animal models of CGN and making a further analysis， it is found that the CGN models are mainly modeled using rats with the methods of single-factor induction or two-factor induction， and the main manifestation of the disease characteristics is nephritis-related symptoms. The single-factor-induced or two-factor-induced CGN rat models have a high fitting degree with the clinical characteristics in western medicine， but the fitting degree is insufficient with the clinical characteristics in traditional Chinese medicine. In addition， the CGN models with syndromes of traditional Chinese medicine are dominated by Qi deficiency in the spleen and kidney and Qi deficiency in the lung and kidney， while models for Yang deficiency in the spleen and kidney， Yin deficiency in the liver and kidney， and deficiency of both Qi and Yin are slightly insufficient. Therefore， it is important to prepare a new and improved animal model of CGN， so that a preclinical model can be provided for the exploration of the pathogenesis of CGN in western medicine and traditional Chinese medicine and its therapeutic research.

Myocardial ischemia-reperfusion injury （MIRI） is one of the major complications of cardiovascular diseases in recent years， seriously threatening the life and health of patients. In recent years， although significant progress has been made in modern medical research on MIRI， due to its complex pathogenesis， adverse drug reactions， and high postoperative risks， there is an urgent need for safer and more effective therapeutic drugs. The pathological effects of MIRI involve inflammatory responses， oxidative stress， apoptosis， and other mechanisms， while Chinese medicine polysaccharide compounds exhibit pharmacological effects such as anti-inflammation， antioxidation， and anti-apoptosis， which are of great significance for improving MIRI. Numerous studies have found that Chinese medicine polysaccharide compounds mainly exert their effects by activating signal pathways such as nerve regenerative factor-1/epidermal growth factor receptor （NRG-1/ErbB）， phosphatidylinositol-3-kinase/protein kinase B （PI3K/Akt）， nuclear factor E₂-related factor 2/heme oxygenase-1 （Nrf2/HO-1）， adenosine 5ʹ-monophosphate-activated protein kinase/silent information regulator 1/peroxisome proliferators-activated receptor γ coactivator lα （AMPK/SIRT1/PGC1α）， Ras homologous gene/Rho kinase （Rho/ROCK）， glycogen synthase kinase 3 （GSK-3）， and P38 mitogen-activated protein kinase （p38-MAPK）， thereby playing a role in improving MIRI. This paper， based on an extensive review of relevant literature in China and abroad， systematically summarizes the latest research findings on the use of Chinese medicine polysaccharide compounds in the treatment of MIRI， analyzes the mechanisms by which these compounds improve MIRI， and explores new therapeutic directions based on the joint investigation of signaling pathways and metabolomics. The paper emphasizes the importance of interdisciplinary cooperation in promoting the development of new drugs， aiming to provide valuable references for the basic research and clinical application of Chinese medicine polysaccharide compounds， ultimately benefiting the majority of cardiovascular disease patients.

Cerebral ischemia-reperfusion injury （CIRI）， a common cerebrovascular disease damage， has garnered increasing attention in the treatment of acute ischemic stroke. Restoration of blood flow and reperfusion to ischemic brain tissue is the key to treatment， while this process often triggers a variety of complex pathophysiological responses， such as oxidative stress， apoptosis， inflammation， mitochondrial dysfunction， angiogenic abnormalities， and disruption of the blood-brain barrier. These responses not only impede the recovery of neurological functions but also may lead to damage or even death of nerve cells， seriously affecting the neurological function and quality of survival of patients. As an important transcription factor， nuclear factor E₂-related factor 2 （Nrf2） has the pharmacological effect of alleviating CIRI by regulating antioxidant， anti-apoptosis， anti-inflammation， mitochondrial function， angiogenesis， and blood-brain barrier pathways. This reveals the potential mechanism of traditional Chinese medicine （TCM） in intervening in CIRI and shows the potential of Nrf2 as a new pathway for dealing with ischemia stroke. This paper comprehensively analyzes the effects and mechanisms of active components and compound prescription of TCM in treating CIRI by modulating the Nrf2 signaling pathway， while pointing out the shortcomings of available studies and proposing a multidimensional exploration. This review aims to provide patients with more comprehensive， safe， and effective therapeutic regimens and improve the quality of survival and prognosis of patients. In addition， in-depth research on TCM should be promoted to reveal the potential mechanism for treating CIRI， providing new ideas and directions for the development of novel therapeutic drugs and methods.

Cerebral ischemia-reperfusion injury （CIRI）， a common cerebrovascular disease damage， has garnered increasing attention in the treatment of acute ischemic stroke. Restoration of blood flow and reperfusion to ischemic brain tissue is the key to treatment， while this process often triggers a variety of complex pathophysiological responses， such as oxidative stress， apoptosis， inflammation， mitochondrial dysfunction， angiogenic abnormalities， and disruption of the blood-brain barrier. These responses not only impede the recovery of neurological functions but also may lead to damage or even death of nerve cells， seriously affecting the neurological function and quality of survival of patients. As an important transcription factor， nuclear factor E₂-related factor 2 （Nrf2） has the pharmacological effect of alleviating CIRI by regulating antioxidant， anti-apoptosis， anti-inflammation， mitochondrial function， angiogenesis， and blood-brain barrier pathways. This reveals the potential mechanism of traditional Chinese medicine （TCM） in intervening in CIRI and shows the potential of Nrf2 as a new pathway for dealing with ischemia stroke. This paper comprehensively analyzes the effects and mechanisms of active components and compound prescription of TCM in treating CIRI by modulating the Nrf2 signaling pathway， while pointing out the shortcomings of available studies and proposing a multidimensional exploration. This review aims to provide patients with more comprehensive， safe， and effective therapeutic regimens and improve the quality of survival and prognosis of patients. In addition， in-depth research on TCM should be promoted to reveal the potential mechanism for treating CIRI， providing new ideas and directions for the development of novel therapeutic drugs and methods.

Objective To compare the differences in the average transaction costs per-referral patients under different models of Integrated Delivery Systems(IDS).Methods Using a typical case sampling method,it selected referred patients from three IDS models:the county medical alliance in D City(Qinghai Province),the urban medical consortium in J District(Zhengzhou City,Henan Province),and the health management coalition in N County(Shandong Province).Structured questionnaires collected demographics,average transaction costs per-referral and cost perceptions.t-tests and ANOVA assessed cost differences;generalized linear regression identified influencing factors.Results Among 915 patients,the average transaction costs per-referral were 1 035.05 yuan(county alliance),195.31 yuan(urban consortium),and 700.97 yuan(health management coalition),with statistically significant differences(P＜0.05).The urban consortium exhibited lower time costs and specialized input costs.Key influencing factors included older age(county alliance),education level,employment status,and referral travel time(urban consortium),as well as urban-rural disparities(health management coalition).Patients'cost perceptions significantly differed across models(P＜0.05).Conclusion The urban medical consortium demonstrated the lowest patient the average transaction costs,highlighting its institutional advantage in minimizing financial burdens.

Objective To compare the differences in the average transaction costs per-referral patients under different models of Integrated Delivery Systems(IDS).Methods Using a typical case sampling method,it selected referred patients from three IDS models:the county medical alliance in D City(Qinghai Province),the urban medical consortium in J District(Zhengzhou City,Henan Province),and the health management coalition in N County(Shandong Province).Structured questionnaires collected demographics,average transaction costs per-referral and cost perceptions.t-tests and ANOVA assessed cost differences;generalized linear regression identified influencing factors.Results Among 915 patients,the average transaction costs per-referral were 1 035.05 yuan(county alliance),195.31 yuan(urban consortium),and 700.97 yuan(health management coalition),with statistically significant differences(P＜0.05).The urban consortium exhibited lower time costs and specialized input costs.Key influencing factors included older age(county alliance),education level,employment status,and referral travel time(urban consortium),as well as urban-rural disparities(health management coalition).Patients'cost perceptions significantly differed across models(P＜0.05).Conclusion The urban medical consortium demonstrated the lowest patient the average transaction costs,highlighting its institutional advantage in minimizing financial burdens.

ObjectiveTo establish a mouse model of basilar artery dolichoectasia （BAD） and explore the mechanism of modified Tongqiao Huoxuetang （JTQHX） in regulating BAD via phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） pathway. MethodSixty C57/BL6 female mice were randomized into sham operation （injected with 10 U·mL^-1 inactivate elastase）， model， atorvastatin calcium tablets （2.6 mg·kg·d^-1）， and low- and high-dose （crude drug 3.4， 17 g·kg^-1·d^-1， respectively） JTQHX groups. The mouse model of BAD was established by injection with 10 U·mL^-1 elastase. After 14 days of modeling， the sham operation group and model group were administrated with equal volumes of pure water by gavage， and other groups with corresponding drugs for 2 months. The levels of interleukin-6 （IL-6） and calpain （LpA） in the serum were measured by enzyme-linked immunosorbent assay （ELISA）. Verhoeff 's Van Gieson （EVG） staining was employed to observe the pathological changes of blood vessels. Terminal-deoxynucleotidyl transferase mediated nick end labeling （TUNEL） was employed to examine the apoptosis rate of vascular smooth muscle cells （VSMCs）. Image Pro Plus was used to observe and calculate the curvature index， elongation length， percentage increase in vessel diameter， and curvature angle of the basilar artery vessels in mice. Western blot was employed to determine the expression levels of PI3K and Akt in the vascular tissue. ResultCompared with the sham operation group， the model group showed lowered IL-6 level （P<0.01）， no significant change in LpA level， increased apoptosis of VSMCs （P<0.01）， and increased curvature index， elongation length， percentage increase in vessel diameter， and curvature angle （P<0.01）. Furthermore， the modeling up-regulated the protein levels of PI3K and Akt in blood vessels （P<0.01） and aggravated the destruction of the inner elastic layer， atrophy of the muscular layer， and hyaline changes in the connective tissue of the medial membrane of the basilar artery wall. Compared with the model group， 2 months of treatment with JTQHX elevated the IL-6 level （P<0.01）， reduced the apoptosis of VSMCs （P<0.01）， decreased the curvature index， elongation length， percentage increase in vessel diameter， and curvature angle （P<0.05， P<0.01）， and down-regulated the protein levels of PI3K and Akt in blood vessels （P<0.01）. In addition， the treatment alleviated the destruction of the inner elastic layer， atrophy of the muscular layer， and hyaline changes in the connective tissue of the medial membrane of the basilar artery wall. ConclusionJTQHX inhibits the elongation， expansion， and curvature of basilar artery vessels and alleviates the pathological changes by reducing the apoptosis of VSMCs and down-regulating the expression of PI3K/Akt pathway.